GLP-1 Medications in the Postpartum Period 

Ozempic, Wegovy, and GLP-1 Medications After Pregnancy 

GLP-1 medications, originally built to treat diabetes, are now one of the most common questions circulating in postpartum spaces. Mothers are asking their providers when they can start. Providers are asking each other what to say when mothers ask. Postpartum prescribing of these drugs is documented as increasing (Bliddal et al., 2025), and most of that increase has nothing to do with diabetes.  

Underneath much of this conversation sits another question that receives far less attention: what is the postpartum body actually trying to accomplish when it holds onto weight? 

And of course we need to be fair about why women are actually seeking these drugs in the first place, because weight loss alone is rarely the whole story. Type 2 diabetes and prediabetes are real, distinct indications, with the strongest evidence base of any use case for this drug class. PCOS, hypertension, sleep apnea, and severe obesity are all conditions where a physician may weigh a GLP-1 as part of treatment, postpartum or not. This article is not arguing that no mother should ever have this conversation with her provider, or that every reason for considering one of these drugs is really just about bouncing back. What follows applies regardless of the reason someone is considering the drug. The body doesn't know why the prescription was written. What changes is the risk-benefit calculation each woman and her provider must make, weighing a real medical indication against a body that is still finishing its own repair work. That calculation belongs to her.  

Therefore, this article does not answer whether GLP-1s are safe or unsafe in the postpartum period. Nobody can answer that for each individual mother, and so because nobody has actually studied it in this population. What this article does is ask what the postpartum body is doing when it holds onto weight in the first place, what happens when that drug meets a body and a gut that is still doing repair work, and how this can impact long term health.

Why Postpartum Weight Retention May Be Protective 

Before any conversation about GLP-1 makes sense, one thing needs to be said: Postpartum fat retention is not a malfunction. It is not evidence of a body that failed to bounce back. In a well- documented body of research, it looks a lot more like design. 

Women preferentially store fat in the hips and thighs, a distribution pattern researchers call gluteofemoral fat. One leading hypothesis for why is that this fat is a reserve built specifically for lactation (Lassek & Gaulin, 2006). Longitudinal studies using skinfold measurement, MRI, and national health survey data all converge on the same finding. This fat accumulates during pregnancy and is preferentially mobilized during lactation, not before. 

It gets more specific than “energy reserve”. Gluteofemoral fat is metabolically protected from use, even under restricted food intake, until late pregnancy and lactation: the exact window of maximal infant brain growth (Lassek & Gaulin, 2008). This fat depot is the primary source of long chain polyunsaturated fatty acids, particularly the omega-3 DHA, which make up roughly a fifth of the dry weight of the human brain. Abdominal fat, by contrast, actually interferes with the enzyme needed to make these fatty acids available. Location matters here, not just quantity. 

So when a body holds onto weight after birth, in this specific gluteofemoral pattern, it may be doing precisely the job it was built to do: provisioning the baby's brain, and surrendering the reserve only once lactation asks for it. 

But fat is only one piece of a larger pattern. Pregnancy and birth draw far more than a single fat store. Iron is mobilized from maternal stores to rebuild blood volume after birth. Minerals are redirected from bone and tissue. Amino acids are diverted from muscle and connective tissue. Every one of these withdrawals happens for a reason: the body is meeting an urgent, immediate demand by borrowing from a reserve it assumes will eventually be repaid. When repayment doesn't happen, across repeated pregnancies, closely spaced births, extended breastfeeding, or simply a postpartum period without enough nourishment or rest, that borrowing compounds. Researchers have described cumulative changes in maternal body composition across repeated pregnancies, while the broader concept of maternal depletion encompasses the progressive loss of maternal nutritional reserves across reproduction. The same compounding logic holds across the mother's broader nutrient status, not only her fat stores (Bower, 2026). 

This is the frame that has to be in place before GLP-1 enters the conversation. The postpartum body is not resisting weight loss out of stubbornness or a broken metabolism. For most women, it is completing a biologically scheduled handoff of resources to a brain that is still being built.

How GLP-1 Medications Work 

Here is where the conversation usually gets confused, understandably, because the marketing around these drugs leans hard on the fact that GLP-1 is “natural.” 

GLP-1, short for glucagon-like peptide-1, is a real hormone the gut already makes. It is secreted by cells in the small intestine after eating. It slows gastric emptying, prompts the pancreas to release insulin, and signals satiety to the brain as part of the gut-brain axis. Your gut has been making this molecule your whole life. 

What is genuinely uncertain is whether obesity involves a true deficiency of this hormone. Some research finds the amount of GLP-1 released after a meal may be somewhat reduced in people with obesity. But other research in the same population finds the hormone's actual appetite suppressing effect is preserved. That is a meaningfully different finding than “the body has run out of GLP-1 and needs to be resupplied.” It points to something closer to a modest signaling shift, not a broken system waiting on a replacement part. 

The drug is not a replacement part in the way it's often marketed. GLP-1 receptor agonists, semaglutide, tirzepatide, liraglutide, bind the same receptor as the body's natural hormone, but they do it continuously, at levels many multiples higher than what the gut produces around a normal meal, and they stay active for days rather than minutes. The body's own GLP-1 is a pulse, tied to eating, cleared within minutes. The drug is a sustained, pharmacological override of that same receptor, running around the clock whether or not a meal has happened. 

Calling that “just supplementing what your body already makes” is a little like calling a fire hose “just water.” The substance is related. The exposure is not comparable.

How GLP-1 Medications Affect the Postpartum 

The postpartum gut is not idle. In the first month after birth, the maternal gut microbiome undergoes measurable, functional reprogramming: shifts in amino acid biosynthesis, changes in which fermentation pathways are active, adjustments that appear to support tissue repair, immune recalibration, and the metabolic demands of lactation. This is a gut in the middle of a project. It is rebuilding, not simply recovering (Bower, 2026). 

Layer a GLP-1 receptor agonist onto that. 

The single most consistently documented effect of these drugs, across every major version, is delayed gastric emptying and slowed whole-gut motility. In one motility study using wireless capsule technology, delayed gastric emptying was observed in 80% of patients, and delayed transit through the entire gut in 44% of this small group. Patients on higher doses had the longest delays and were the only ones with slowed small bowel transit as well. This is not a side effect at the margins. It is close to the primary mechanism of action. 

GLP-1 also directly suppresses bile acid synthesis, gallbladder release, and bile reabsorption in the ileum. Slower motility plus suppressed bile flow adds up to biliary stasis: bile sitting still longer than it should, supersaturated with cholesterol. A meta-analysis of 76 randomized trials and more than 100,000 patients found this translates into real, statistically significant risk for cholelithiasis, cholecystitis, and other biliary disease. None of this is speculative. It is the documented cost of how the drug works. 

This connects directly to something already true of the postpartum gallbladder, with or without a GLP-1 prescription. Biliary sludge, the precursor state to gallstones, develops in roughly a third of pregnant women by the third trimester, with new gallstones forming in a smaller but real share of that group (Ko et al., 2005). In most women, this sludge clears on its own after birth as estrogen falls and gallbladder motility recovers. But for a meaningful portion of postpartum mothers, that clearing does not happen. Sludge persists, progresses to stones, and cholecystectomy, gallbladder removal, is the second most common non-obstetric surgery performed on pregnant and postpartum women, after appendectomy (Nan et al., 2023; Singhal et al., 2025). That is the baseline risk before a GLP-1 prescription ever enters the picture: a gallbladder already working against elevated cholesterol saturation and reduced motility left over from pregnancy. Layering a drug class whose most consistent, best documented effect is further suppressing gallbladder motility and bile flow onto that baseline is not a neutral addition. It is compounding a risk that is already elevated, in an organ already more likely to be struggling, at the exact time it is trying to recover. 

Even more, in one animal study, GLP-1 receptor agonist administration increased populations of E. coli in the gut and activated sympathetic nervous system signaling into the intestinal tract. In healthy mice, this didn't cause harm on its own. But in mice with existing gut inflammation, it came with weakened intestinal barrier integrity and bacterial translocation, meaning gut bacteria crossing into places they shouldn't be. This was one study, in mice, under compromised conditions. It is not proof of what happens in a postpartum human gut. But it is a real, published signal that this drug class does not leave gut architecture untouched, and it deserves to be known before anyone assumes it doesn't apply here. 

Put plainly: a postpartum gut is already renegotiating motility, bile flow, and microbial composition to finish a repair job. GLP-1 receptor agonists' most consistent, best documented effects land on exactly those same three systems. Nobody has studied what happens when both are underway at once, in the same body, in the same six to twelve week window. That is not a footnote. That is the actual research gap. 

Can You Take GLP-1 Medications While Breastfeeding? 

The question every breastfeeding mother eventually asks is some version of: does this get into my milk? 

Here the data is, honestly, more reassuring than a lot of the online conversation suggests. In the first dedicated human study on this question, researchers collected milk samples from eight women using subcutaneous semaglutide and could not detect the drug in any sample. Even using a deliberately conservative worst-case estimate, the maximum possible dose to an infant came out to 1.26% of the maternal dose, well under the 10% threshold generally used to call a medication compatible with breastfeeding (Diab et al., 2024). That is a genuinely good finding, and it deserves to be reported as one. 

It comes with real limits, though. Eight women is a small sample. And every major GLP-1 trial that established these drugs' safety and efficacy specifically excluded anyone who was pregnant or breastfeeding, which means the population now using these drugs postpartum was never actually studied in the trials that got them approved. “Not detected” in eight milk samples is a floor, not a verdict.

Can GLP-1 Medications Reduce Milk Supply? 

The bigger practical concern for breastfeeding mothers may not be drug transfer at all. It may be appetite suppression itself, arriving at exactly the moment the body needs to eat enough to establish and sustain supply. Milk production is established and regulated most rapidly during the early postpartum weeks. A drug whose entire mechanism is reducing hunger, layered onto a body that needs a nourishment surplus to heal and make milk, is not a small thing to hold at the same time, regardless of what shows up in a milk sample. 

Then there is the nutrient question, which is where this becomes about more than milk transfer. Large scale data on GLP-1 users generally, not postpartum-specific, found that over 22% developed at least one measurable nutrient deficiency within twelve months, most commonly vitamin D, followed by thiamine, other B vitamins, and anemia. A meaningful share of total weight lost on these drugs is lean body mass rather than fat, in some studies as much as 15-40% of total weight lost (Pantazopoulos et al., 2025).

GLP-1 Medications, Protein Intake, and Postpartum Recovery 

Protein is where this gets specific, and it deserves its own attention, because the standard most people are measured against is already too low. The adult protein RDA, 0.8 grams per kilogram of body weight daily, was derived from nitrogen balance studies: the minimum intake needed to avoid net protein loss over time. It is a maintenance number. It answers the question “what keeps a stable body from falling behind,” not “what does a body need to rebuild.” Postpartum is not maintenance. It is uterine involution, blood volume restoration, collagen and connective tissue repair, and, for a breastfeeding mother, the ongoing synthesis of milk itself. Applying a maintenance-level target to a body doing reconstruction work was already a mismatch before any medication entered the picture. 

Preserving lean mass during weight loss requires meaningfully more protein than that baseline, generally cited around 1.2 to 2.0 grams per kilogram daily (Johnson et al., 2025). The research on who is actually hitting that target while on a GLP-1 is not encouraging. In one cross-sectional study, 75% of participants using a GLP-1RA reported eating more protein since starting the medication, but when intake was measured against body weight, only 43% reached even 1.2 g/kg, only 10% reached 1.6 g/kg, and just 5% reached 2.0 g/kg (Johnson et al., 2025). Appetite suppression does not selectively spare protein. It reduces total volume, and protein, which typically requires more deliberate effort to prioritize than easier-to-tolerate carbohydrates, is often the first casualty of a smaller appetite. 

Lay the postpartum protein deficit and the GLP-1 protein deficit on top of each other and the picture is not two separate small problems. It is one compounding one: a body already being asked to rebuild on a maintenance-level standard, using a drug that makes hitting even that maintenance standard harder, at a moment when lactation is asking for more protein still. Lactation already asks the body for more of nearly everything it has. Layering a drug that suppresses intake and appears to draw down lean tissue onto a body that is simultaneously making milk and rebuilding its own reserves is not a hypothetical stacking of risk. It is two documented processes happening in the same body, at the same time, that nobody has studied together. 

What We Still Don't Know About GLP-1 Medications Postpartum 

Here is the honest state of the evidence: 

There is no dedicated postpartum trial of GLP-1 receptor agonists. Every figure in this article, motility, bile flow, nutrient deficiency, lean mass loss, comes from general adult populations and has been extrapolated onto postpartum women by inference, not by study. 

There is no consensus protocol for micronutrient monitoring in anyone on these drugs, postpartum or otherwise. There is no formal, evidence-based screening guideline for eating disorder risk in this specific population, despite clinicians already reporting that appetite suppression can mask or accelerate disordered eating patterns. There is no research on what happens when a postpartum gut, already reallocating motility and bile flow for its own repair, is asked to also absorb the motility and bile effects of this drug class. And there is no data at all on the timing question mothers ask most: how long after weaning it is actually safe to start, beyond providers' best-guess estimates based on the drug's half-life. 

This is not a gap to explain away. It is the honest shape of what is known and not known, and it should shape how confidently anyone, mother or provider, treats a postpartum prescription as a settled decision rather than an open question currently being answered in real time, on real bodies, without a trial behind it.

The Verdict 

The postpartum body was never broken for holding onto weight. It was finishing a job that predates every GLP-1 trial by roughly all of human history. Before that reserve gets pharmacologically overridden, the honest answer to “is this safe” is that nobody has actually checked. And the gut, quietly, is where that question will eventually get answered.

This is the level of pattern recognition taught inside The Postpartum Body — how to read what a mother's body is actually communicating, instead of defaulting to the nearest available explanation. Whether you're a mother trying to understand your own postpartum experience, or a provider who has felt the limits of “it's just hormones” in your own practice, this is where that gap gets closed. 

Learn More About The Postpartum: thepostpartumbody.com. 

References 

• Bliddal, M., Nohmie, G., Damkier, P., & Pottégard, A. (2025). Increasing postpartum use of GLP-1 receptor agonists. JAMA, 334(24), 2227–2229. https://doi.org/10.1001/jama.2025.20947 

• Bower, M. (2026). Postpartum digestion is not normal digestion: Why nutrition must change after birth. Journal of Prenatal and Perinatal Psychology and Health, 40(1), 101–111. 

• Diab, H., Fuquay, T., Datta, P., Bickel, U., Thompson, J., & Krutsch, K. (2024). Subcutaneous semaglutide during breastfeeding: Infant safety regarding drug transfer into human milk. Nutrients, 16(17), 2886. https://doi.org/10.3390/nu16172886 

• Nan, X., Chan, E., Wong, K. S., Ng, J., Izwan, S., Cooper, M., & Damodaran, R. (2023). Laparoscopic cholecystectomy in pregnancy: A seven-year retrospective study from an Australian tertiary center. Cureus, 15(12), e50034. https://doi.org/10.7759/cureus.50034 

• Johnson, B., Milstead, M., Thomas, O., McGlasson, T., Green, L., Kreider, R., & Jones, R. (2025). Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: A cross-sectional study. Frontiers in Nutrition, 12, 1566498. https://doi.org/10.3389/fnut.2025.1566498 

• Ko, C. W., Beresford, S. A. A., Schulte, S. J., Matsumoto, A. M., & Lee, S. P. (2005). Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology, 41(2), 359–365. https://doi.org/10.1002/hep.20534 

• Lassek, W. D., & Gaulin, S. J. C. (2006). Changes in body fat distribution in relation to parity in American women: A covert form of maternal depletion. American Journal of Physical Anthropology, 131(2), 295–302. 

• Lassek, W. D., & Gaulin, S. J. C. (2008). Waist-hip ratio and cognitive ability: Is gluteofemoral fat a privileged store of neurodevelopmental resources? Evolution and Human Behavior, 29(1), 26–34. 

• Pantazopoulos, D., Gouveri, E., Papazoglou, D., & Papanas, N. (2025). GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review. Diabetes Research and Clinical Practice, 229. https://doi.org/10.1016/j.diabres.2025.109386 

• Singhal, V. K., Alaswad, F. D., Senofer, N., Ojha, V., & Md Suleman, A. (2025). The outcome of laparoscopic cholecystectomy in pregnant women. Cureus, 17(3), e80005. https://doi.org/10.7759/cureus.80005 

This article is original research synthesis by
Maranda Bower, founder of Postpartum University®.

This research was originally published November, 2025.
You’re welcome to share excerpts or discuss these ideas publicly. When doing so, please credit the original work to Maranda Bower / Postpartum University® and link back to this article when possible.

To cite this article:
Bower M. GLP-1 Medications in the Postpartum Period. 2026. https://postpartumu.com/research/glp-1-postpartum/